- Home
- GTEC vs APM Comparison
GTEC vs APM Comparison
Compare GTEC & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | APM |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 18.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GTEC | APM |
|---|---|---|
| Price | $1.01 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 223.8K | 108.9K |
| Earning Date | 11-07-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | N/A |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.65 |
| 52 Week High | $2.92 | $7.49 |
Technical Indicators
Market Signals| Indicator | GTEC | APM |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 40.40 |
| Support Level | $0.92 | $1.22 |
| Resistance Level | $1.09 | $1.38 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 25.71 | 15.69 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.